COVID-IHU #7
Version 1 du 14 avril 2020
In vitro antiviral activity of doxycycline against SARS-CoV-2
Matthieu Gendrot, Julien Andreani, Priscilla Jardot, Sébastien Hutter, Manon Boxberger, Joel Mosnier, Marion Le Bideau, Isabelle Duflot, Isabelle Fonta, Clara Rolland, Hervé Bogreau, Bernard La Scola, Bruno Pradines
Abstract :
In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Identifying effective antiviral drugs is urgently needed. An efficient approach to drug discovery is to evaluate whether existing approved drugs can be efficient against SARS-CoV-2. Doxycycline, which is a second-generation tetracycline with broadspectrum antimicrobial, antimalarial and anti-inflammatory activities, showed in vitro activity against SARS-CoV-2 with median effective concentration (EC50) of 5.6 ± 0.4 µM. Doxycycline, with its antiviral and anti-inflammatory activities, could be used in prophylaxis of COVID-19 at 100 mg day in combination with chloroquine, or in treatment at 200 mg day during 10 days in combination with hydroxychloroquine.
